DSM Firmenich (OTCPK:DSFI.Y) Update / briefing Transcript

Summary of the Investor Event 2026 Conference Call Company Overview - The company is focused on the Animal Nutrition & Health sector, which has undergone significant transformation and portfolio tuning to enhance growth and profitability [1][2][3][4] - The company has achieved a size of EUR 9 billion, with an average organic sales growth of 4.5% per year, aligning with industry peers [10][31] Key Financial Metrics - The EBITDA margin has improved from 14% to nearly 20%, with a projected step-up of EUR 300 million in EBITDA from 2023 to 2025 [10][31] - The company aims for a cash conversion rate of 11%-12% for 2026, with a long-term target of 14% or higher by 2028 [37][46] Business Strategy and Growth Drivers - The company has split its Animal Nutrition & Health business into two segments: Solutions Co (specialty) and Essential Co (vitamins) to mitigate volatility and enhance profitability [5][6][7] - Focus on high-growth areas such as enzymes, cultures, probiotics, and fine fragrances, particularly in emerging markets like India, Africa, and Asia [38][40][41] - Emphasis on innovation in health and nutrition, particularly in women's health and preventative healthcare, to capture new market opportunities [16][41] Market Challenges - The company faces headwinds from foreign exchange fluctuations, with an estimated negative impact of CHF 100 million in 2024 and 2025, and CHF 70 million in 2026 [18][19] - A cautious consumer demand has been observed, particularly in North America, affecting inventory levels and purchasing behavior [19][20] Sustainability and Employee Engagement - The company has achieved a CDP double A rating on water and climate, indicating a strong commitment to sustainability, which is increasingly important to customers [9][10] - Employee engagement remains stable at around 80%, reflecting a positive internal culture despite ongoing changes [10] Technological Integration - The company is leveraging AI for ingredient discovery, production optimization, and enhancing the brief-to-adoption process, resulting in significant efficiency gains [25][26][30] - AI is seen as a tool to support, not replace, the creative roles of perfumers and flavorists, ensuring the company remains competitive [27][29] Future Outlook - The company projects organic sales growth of 2%-4% for 2026, with potential acceleration to 4%-6% in 2027 as market conditions normalize [37][42] - The focus will remain on optimizing existing operations and enhancing profitability through cost control and operational excellence [47][48] Conclusion - The company is positioned for growth through strategic portfolio management, innovation in health and nutrition, and a commitment to sustainability, while navigating market challenges and leveraging technology for operational efficiency [48]